Recruitment and eligibility in a Phase 1 early Alzheimer's disease trial of Sabirnetug.

ABSTRACT:

Introduction

Historically underrepresented racial and ethnic groups may face a higher risk and burden of dementia but continue to be underrepresented in Alzheimer's disease (AD) clinical research. Recent efforts have been insufficient to identify and address race-related disparities in recruitment and eligibility for AD clinical trials.

Methods

INTERCEPT-AD was a Phase 1 randomized, placebo-controlled, double-blind, first-in-human study of sabirnetug (ACU193) in participants with early symptomatic AD (mild cognitive impairment [MCI] or mild dementia due to AD). Participants were referred through seven site-selected recruitment strategies across 17 study sites in the United States (June 2021-January 2023). Numbers of pre-screened (n = 1025), screened (n = 260),

SUBMITTER: Moxon R 

PROVIDER: S-EPMC12504043 | biostudies-literature | 2025 Oct-Dec

REPOSITORIES: biostudies-literature